Holen Sie sich die Stockscreener-App
28.34
0.60%
-0.17
Handel nachbörslich:
28.23
-0.11
-0.39%
Schlusskurs vom Vortag:
$28.51
Offen:
$28.23
24-Stunden-Volumen:
2.82M
Relative Volume:
0.45
Marktkapitalisierung:
$3.60B
Einnahmen:
Nettoeinkommen (Verlust:
$-472.34M
KGV:
-6.8357
EPS:
-4.1459
Netto-Cashflow:
$-340.33M
1W Leistung:
-3.21%
1M Leistung:
-11.38%
6M Leistung:
-17.28%
1J Leistung:
-15.55%
1-Tages-Spanne:
$27.91
$28.84
1-Wochen-Bereich:
$27.05
$29.71
52-Wochen-Spanne:
$25.77
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
28.34 | 3.60B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-28 | Eingeleitet | Lake Street | Buy |
| 2026-05-27 | Fortgesetzt | Truist | Buy |
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. - The Motley Fool
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Viking Therapeutics Inc (Derivatives) to Chinese Yuan Price Today | Live VKTX to CNY Converter & Exchange Rate - CryptoRank
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know - Zacks Investment Research
Viking Therapeutics Inc (Derivatives) - CryptoRank
Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months - Yahoo Finance
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Zacks Investment Research
VKTX Advances Obesity Program With New Oral Maintenance Study - Zacks Investment Research
Viking Therapeutics starts oral trial as Truist targets Viking Therapeutics stock at USD 87 - AD HOC NEWS
Viking Therapeutics Starts VK2735 Obesity Maintenance Trial - grafa.com
VKTX Down 16% in a Month: Time to Invest or Exit the Stock? - Yahoo Finance
VKTX Down 16% in a Month: Time to Invest or Exit the Stock? - TradingView
Viking Therapeutics begins oral VK2735 maintenance trial in obesity - Mugglehead Investment Magazine
Viking Therapeutics initiates oral maintenance dosing study - Investing.com
Viking Therapeutics Inc (Derivatives) price today, VKTX to USD live price, marketcap and chart - CoinMarketCap
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity - PR Newswire
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity - Yahoo Finance
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock - The Motley Fool
Here Are My Top 4 Stocks to Buy in October - The Motley Fool
VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing - Stocktwits
VKTXObesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis - Simply Wall Street
Viking Therapeutics Inc (MIL:1VKTX) Stock Price, Trades & News - GuruFocus
Does Viking Therapeutics (VKTX) Pairing VK2735 Data With Fresh Capital Signal A Sharpened Obesity Strategy? - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) - Yahoo! Finance Canada
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price? - Yahoo Finance
Prediction: This Stock Could Double Over the Next 5 Years - The Motley Fool
Inventory turnover of Viking Therapeutics, Inc. – HAN:1VT - TradingView
Viking Therapeutics Slides as Financing Overhang Appears to Weigh on Shares - Quiver Quantitative
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors - Zacks Investment Research
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - The Motley Fool
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - sg.finance.yahoo.com
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - Yahoo Finance
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks - Yahoo Finance
Viking Therapeutics (VKTX) Raises $575M in Upsized Stock and Con - GuruFocus
Viking Therapeutics Raises Capital via Equity and Convertibles - TipRanks
Viking Therapeutics Raises $547.8 Million via Equity Sale and 2.00% Convertible Notes - TradingView
Viking Therapeutics raises $575 million in dual offering - Investing.com
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes - Morningstar
About $575 million came in for Viking Therapeutics, including $258.75 million in debt that can turn into shares. - Stock Titan
Viking Therapeutics (VKTX) Closes Upsized Stock and 2.00% Convertible Notes Offerings, ~$575M Gross - TradingView
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes - Yahoo Finance
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes - PR Newswire
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (VKTX) - Seeking Alpha
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viking Therapeutics Inc-Aktie (VKTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 29 '26 |
Sale |
33.47 |
21,217 |
710,141 |
212,204 |
| MARIANNA MANCINI | Officer |
Jul 29 '26 |
Proposed Sale |
33.47 |
18,217 |
609,636 |
0 |
| GREG ZANTE | Officer |
Jul 29 '26 |
Proposed Sale |
33.47 |
21,217 |
710,141 |
0 |
| BRIAN LIAN | Officer |
Jul 29 '26 |
Proposed Sale |
33.32 |
148,517 |
4,947,888 |
0 |
| Mancini Marianna | Chief Operating Officer |
Jul 29 '26 |
Sale |
33.47 |
18,217 |
609,636 |
422,760 |
| Aubuchon Neil William | Chief Commercial Officer |
Mar 10 '26 |
Buy |
33.50 |
4,475 |
149,912 |
4,475 |
| MARIANNA MANCINI | Officer |
Jan 05 '26 |
Proposed Sale |
32.98 |
57,661 |
1,901,406 |
0 |
| GREG ZANTE | Officer |
Jan 05 '26 |
Proposed Sale |
32.98 |
57,661 |
1,901,470 |
0 |
| BRIAN LIAN | Officer |
Jan 05 '26 |
Proposed Sale |
32.96 |
233,409 |
7,692,134 |
0 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
5.35%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):